Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis.
Benjamin MiaoNitesh SoodThomas J BunzCraig I ColemanPublished in: European journal of haematology (2020)
In NVAF patients with ESRD and/or receiving dialysis, rivaroxaban and apixaban were associated with similar risks of SSE and major bleeding.
Keyphrases
- end stage renal disease
- atrial fibrillation
- chronic kidney disease
- peritoneal dialysis
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- venous thromboembolism
- risk assessment
- coronary artery disease
- pulmonary embolism